H 103

Drug Profile

H 103

Alternative Names: H-103; Oncolytic recombinant adenovirus injection - Shanghai Sunway Biotech

Latest Information Update: 08 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shanghai Sunway Biotech
  • Class Antineoplastics; Cancer vaccines; DNA vaccines; Gene therapies; Oncolytic viruses
  • Mechanism of Action P53 gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 08 Oct 2015 Phase-I clinical trials in Cancer in China (Intratumoural) before October 2015
  • 08 Oct 2015 Shanghai Sunway Biotech completes a phase I trial in Cancer in China (Shanghai Sunway Pipeline, October 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top